Category - Developments

Developments

Akari gets FDA orphan drug designation for nomacopan

Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients. HSCT...

August 30, 2019

Developments

Zenabis outperforms cannabis design capacity by 46% in July

Zenabis Global’s (TSX:ZENA) cultivation output in July 2019 was 1,238 kg of dried cannabis, which represents a 46.2% outperformance relative to original design capacity and a 12.9% outperformance relative to revised...

August 28, 2019

Developments

Zenabis inks agreement for cannabis-infused beverage inputs

Zenabis Global (TSX:ZENA) has secured a supply of cannabis-infused inputs for the production of cannabis-infused beverages and other products. Under the accord, Zenabis will provide cannabis to anunnamed beverage...

August 27, 2019

Developments

Satsuma Pharma doses first patient in Phase 3 migraine trial

Closely-held Satsuma Pharmaceuticals dosed the first patient in its Phase 3 efficacy trial of STS101 for the acute treatment of migraine. STS101 is a drug-device combination of dihydroergotamine mesylate (DHE) dry...

August 23, 2019

Developments

BeyondSpring’s Plinabulin demonstrates superior quality of life for prevention of neutropenia

BeyondSpring (NASDAQ: BYSI) plans to present positive data in an abstract titled, “Quality of Life (QoL) in Advanced NSCLC Patients Treated with Docetaxel and with Either Plinabulin or Pegfilgrastim for the Prevention...

August 23, 2019

Developments

Eiger gets FDA breakthrough therapy designation for HDV drug candidate

Eiger BioPharmaceuticals’ (NASDAQ:EIGR) peginterferon lambda (lambda) received FDA breakthrough therapy designation for the treatment of hepatitis delta virus (HDV) infection. HDV is the most severe form of human viral...

August 21, 2019

Developments

Zenabis in $25-million of additional debt financing; extension and partial conversion of notes

Zenabis Global (TSX:ZENA) signed definitive documentation for $25-million of new senior secured debt financing from R.C. Morris Capital Management. The financing involved amending and restating the debenture...

August 21, 2019

Developments

Cerecor gets FDA fast track designation for CERC-802

Cerecor (NASDAQ:CERC) received FDA fast track designation for CERC-802 for the treatment of mannose-phosphate isomerase deficiency, also known as CDG-1b. CDG-1b is a rare genetic disease that impacts carbohydrate...

August 21, 2019

Developments

Outlook Therapeutics completes enrollment in Phase 3 wet AMD trial

Outlook Therapeutics (NASDAQ:OTLK) completed patient enrollment in its Phase 3 clinical trial comparing ONS-5010 to ranibizumab for the treatment of wet age-related macular degeneration (AMD). Administered via...

August 20, 2019

Developments

Myovant Sciences completes recruitment for Phase 3 endometriosis study

Myovant Sciences (NASDAQ:MYOV) completed patient recruitment for its first of two Phase 3 studies of relugolix combination therapy for the treatment of endometriosis-associated pain. Relugolix is a once daily, oral...

August 20, 2019

Category - Developments

Subscribe